fig1
Figure 1. Schematic representation of AMG 160, a BiTE targeting PSMA on tumor cells and CD3 on T cells. By simultaneously binding to PSMA-expressing prostate cancer cells and CD3 on T cells, AMG 160 facilitates T cell-mediated cytotoxicity against tumor cells. BiTE: Bispecific T cell engager; PSMA: prostate-specific membrane antigen.
